Oncology Central

ASCO18: PRODIGE 7 demonstrates that HIPEC may not be necessary for CRC patients

The PRODIGE 7 randomized, Phase III study, presented at ASCO 2018, has demonstrated that, for advanced colorectal cancer patients, hyperthermic intra-peritoneal chemotherapy (HIPEC) (heated chemotherapy) delivered to the abdomen during surgery, may not be necessary.
To view restricted content, please:



News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.